Become a member

INTER Courses

Mastering biotechnologies and therapeutic innovations

New

Level 1 -

Fundamentals of Oncology

Presentation

Why participate?
Present the characteristics of tumor cells and the causes of therapeutic failure. Offer solutions through innovative therapies

Training context
Cancer accounts for a significant share of global mortality, with multiple and complex causes that traditional therapeutic approaches alone cannot fully address. It is essential to understand the reasons behind these failures in order to envision tomorrow’s innovative therapies.

Learning objectives

  • Understand the basics of cancer: Definitions, classifications, and risk factors
  • Identify the characteristics of tumor cells: Properties and development mechanisms
  • Learn about the main tumor treatments: Surgery, radiotherapy, chemotherapy, immunotherapy
  • Analyze therapeutic failures: Causes of recurrence, pharmacokinetics, tumor heterogeneity
  • Explore innovative therapies and preclinical models: CAR-T cells, gene therapy, vaccines, oncolytic viruses, in vitro and in vivo models

Content

Welcome and participant introductions

Introduction

  • Cancer in key figures

  • Cancer: definitions

  • Classification of cancers

  • Main risk factors

Properties of tumor cells

  • Key characteristics of a tumor cell

  • Fundamental aspects of cancer development

Main treatments for tumors

  • Surgery

  • Radiotherapy

  • Chemotherapy

  • Immunotherapy

Recurring issues in therapeutic failures

  • Recurrence due to incomplete elimination

  • Pharmacokinetic problems

  • Tumor mass heterogeneity

Advanced Therapy Medicinal Products (ATMPs)

  • CAR-T cells and gene therapy

  • Vaccines

  • Oncolytic viruses

Main models for preclinical proof of concept

  • In vitro models

  • In vivo models

General discussion, conclusion, and evaluation

Teaching methods

Interactive Teaching, Case Studies, Experience Sharing

Audience

Researchers, technicians involved in tumor research and antitumor therapy programs

Prerequisites

Basic knowledge of cell biology. Familiarity with preclinical drug development and/or pharmacology

Duration

1 day, 7 hours

Price

750 € HT (Public)
600 € HT (Membre)
300 € HT (Académique)

Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.

Rating

There is no rating available because this training session was never carried out.

The benefits of our courses

  • Personalized support
  • Skills assessment
  • Certificate of completion
  • Training quality evaluation
  • Accessible to people with disabilities (please contact us)

How to access and deadlines

Registering online or by e-mail is a pre-registration. We will process your request within one week:

  • Contact by e-mail or telephone
  • Sending of administrative and educational documents: training agreement, training programme and positioning questionnaire.

Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.

When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.

For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr

Jean-Roch Fabreguettes

MEARY

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris

Jean-Roch Fabreguettes est un spécialiste de la recherche translationnelle et des phases précoces de développement clinique des médicaments de thérapie innovantes (MTI). Pharmacien, titulaire d’un doctorat de l’Université de Montpellier 1, il a travaillé plus de 25 ans dans le domaine et a contribué, pour des équipes académiques comme pour des start-ups, à la réalisation de plus de 30 programmes de recherche sur différents types de MTI : thérapie génique in vivo ou ex vivo, thérapie cellulaire, ingénierie tissulaire… Il est actuellement Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris. Le centre MEARY est une plateforme de l’Assistance Publique – Hôpitaux de Paris (AP-HP), dédiée à la fabrication de médicament de thérapie innovante expérimentaux. Laboratoire membre de l’ISCT, il est autorisé par l’ANSM et dispose d’un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliqué dans le développement clinique et la fabrication de nombreux MTI : CAR-T cells, lymphocytes T régulateurs, cellules stromales mésenchymateuses…

Précédemment, Jean-Roch Fabreguettes a été expert Qualité (CMC) auprès de l’ANSM durant 9 ans et a conseillé différentes sociétés de biotechnologies. Il est un intervenant régulier pour l’Université Paris Cité et un membre actif de l’ISCT et de réseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).